EGFR and cancer: MRP1, MRP3, MRP4, and MRP5, for instance, have often been found to be overexpressed in gastric adenocarcinoma (GAC), a highly chemoresistant cancer driven by oncogene activation, particularly through the upregulation of efflux pumps via the EGFR, Ras, or MYC pathways [158,159,160].